JP2024500288A - Ｋｒａｓ変異癌の治療 - Google Patents

Ｋｒａｓ変異癌の治療 Download PDF

Info

Publication number
JP2024500288A
JP2024500288A JP2023530278A JP2023530278A JP2024500288A JP 2024500288 A JP2024500288 A JP 2024500288A JP 2023530278 A JP2023530278 A JP 2023530278A JP 2023530278 A JP2023530278 A JP 2023530278A JP 2024500288 A JP2024500288 A JP 2024500288A
Authority
JP
Japan
Prior art keywords
vorciclib
days
cancer
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530278A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022109307A5 (https=
JP2024500288A5 (https=
Inventor
ワイリー，サンドラ・イー
ゴールド，ダニエル・ピー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of JP2024500288A publication Critical patent/JP2024500288A/ja
Publication of JPWO2022109307A5 publication Critical patent/JPWO2022109307A5/ja
Publication of JP2024500288A5 publication Critical patent/JP2024500288A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023530278A 2020-11-19 2021-11-19 Ｋｒａｓ変異癌の治療 Pending JP2024500288A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115969P 2020-11-19 2020-11-19
US63/115,969 2020-11-19
US202163154652P 2021-02-26 2021-02-26
US63/154,652 2021-02-26
US202163158849P 2021-03-09 2021-03-09
US63/158,849 2021-03-09
US202163173361P 2021-04-10 2021-04-10
US63/173,361 2021-04-10
PCT/US2021/060151 WO2022109307A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Publications (3)

Publication Number Publication Date
JP2024500288A true JP2024500288A (ja) 2024-01-09
JPWO2022109307A5 JPWO2022109307A5 (https=) 2024-11-27
JP2024500288A5 JP2024500288A5 (https=) 2024-11-27

Family

ID=81709695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530278A Pending JP2024500288A (ja) 2020-11-19 2021-11-19 Ｋｒａｓ変異癌の治療

Country Status (9)

Country Link
US (1) US20240016781A1 (https=)
EP (1) EP4247806A4 (https=)
JP (1) JP2024500288A (https=)
KR (1) KR20230148144A (https=)
AU (1) AU2021381423A1 (https=)
CA (1) CA3198938A1 (https=)
IL (1) IL302925A (https=)
MX (1) MX2023005806A (https=)
WO (1) WO2022109307A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4376839A4 (en) * 2021-07-26 2025-10-15 Vincerx Pharma Inc SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
IL319991A (en) * 2022-10-03 2025-06-01 Prelude Therapeutics Inc Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies
WO2024173833A1 (en) * 2023-02-16 2024-08-22 Mei Pharma, Inc. Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525097A (ja) * 2013-07-12 2016-08-22 ピラマル エンタープライズイズ リミテッド 黒色腫の治療のための組合せ医薬
JP2019514854A (ja) * 2016-03-28 2019-06-06 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
JP2020105162A (ja) * 2018-11-19 2020-07-09 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020210760A1 (en) * 2019-04-11 2020-10-15 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
US20220175750A1 (en) * 2018-04-23 2022-06-09 The Regents Of The University Of California Sustained release formulation for local delivery of cdk9 inhibitors
WO2020046966A1 (en) * 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
CA3148504A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2022217133A1 (en) * 2021-04-10 2022-10-13 Mei Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525097A (ja) * 2013-07-12 2016-08-22 ピラマル エンタープライズイズ リミテッド 黒色腫の治療のための組合せ医薬
JP2019514854A (ja) * 2016-03-28 2019-06-06 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
JP2020105162A (ja) * 2018-11-19 2020-07-09 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020210760A1 (en) * 2019-04-11 2020-10-15 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof

Also Published As

Publication number Publication date
AU2021381423A1 (en) 2023-06-22
KR20230148144A (ko) 2023-10-24
WO2022109307A1 (en) 2022-05-27
US20240016781A1 (en) 2024-01-18
EP4247806A4 (en) 2024-11-13
IL302925A (en) 2023-07-01
CA3198938A1 (en) 2022-05-27
EP4247806A1 (en) 2023-09-27
AU2021381423A9 (en) 2024-02-08
MX2023005806A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
JP2024500288A (ja) Ｋｒａｓ変異癌の治療
TWI428336B (zh) Ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑之組合
JP6133211B2 (ja) 骨髄線維症を処置するための組成物及び方法
CN116507620A (zh) Cdk4抑制剂的固体形式
AU2022216284A9 (en) Combination therapy for treating abnormal cell growth
TW202002983A (zh) 組合療法
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
WO2016025621A1 (en) Methods of treatment using an erk inhibitor
TWI638818B (zh) ２－（４－（２－（１－異丙基－３－甲基－１ｈ－１，２，４－三唑－５－基）－５，６－二氫苯并［ｆ］咪唑并［１，２－ｄ］［１，４］氧氮呯－９－基）－１ｈ－吡唑－１－基）－２－甲基丙醯胺之多晶型、製造方法及醫藥用途
AU2016342352A1 (en) Heterocyclic PDK1 inhibitors for use to treat cancer
KR20120099219A (ko) 조합물
US20240197680A1 (en) Voruciclib dosing regimens and methods of treatment including the same
JP2026505728A (ja) ６－（３－（（５－クロロ－２－メトキシピリジン）－３－スルホンアミド）－２，６－ジフルオロフェニル）－ｎ－メチルイミダゾ［１，５－ａ］ピラジン－１－カルボキサミドの結晶形態及びその使用方法
CN117043159A (zh) Kras突变型癌症的治疗
HK40103356A (zh) Kras突变型癌症的治疗
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer
KR20120099218A (ko) 조합물
HK40102219A (zh) 沃鲁西林给药方案和包含所述方案的治疗方法
WO2025006569A1 (en) Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
JP2024502130A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤の形態及び製剤
WO2026064575A1 (en) Methods for treating cancer
CN117580571A (zh) 沃鲁西林给药方案和包含所述方案的治疗方法
EA047200B1 (ru) Введение доз ингибитора kras для лечения форм рака
HK1175125B (en) Combinations of a pi3k inhibitor and a mek inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126